Effect of sevelamer hydrochloride exposure on carotid intima media thickness in hemodialysis patients

Nephron - Clinical Practice

Volumn 117, Issue 2, 2011, Pages

  Boaz, M ^a   Katzir, Z ^b   Schwartz, D ^c,d   Gafter, U ^d,e   Biro, A ^b   Shtendik, L ^b   Kon, V ^c   Chernin, G ^c   Weinstein, T ^c,d  

^a Epidemiology and Research Unit   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e RABIN MEDICAL CENTER   (Israel)

Author keywords

Cardiovascular disease; Carotid artery; Chronic kidney disease; Femoral artery; Intima media thickness; Sevelamer hydrochloride

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHORUS; SEVELAMER;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; BODY WEIGHT; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; ECHOGRAPHY; FEMALE; FEMORAL ARTERY; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; ULTRASOUND;

AGED; CAROTID ARTERIES; FEMALE; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MALE; ORGAN SIZE; POLYAMINES; RENAL DIALYSIS; TREATMENT OUTCOME; TUNICA INTIMA;

EID: 77955179099     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319654     Document Type: Article

References (28)

1. Block GA, Klassen PS, Lazarus M, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218.
2. Eddington H, Heaf GJ: Clinical management of disturbances of calcium and phosphate metabolism in dialysis patients. NDT Plus 2009;2:267-272.
3. Ketteler M, Shlieper G, Floege J: Calcification and cardiovascular health: new insights into an old phenomenon. Hypertension 2006;47:1027-1034.
4. Mizobuchi M, Towler D, Slatopolsky E: Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 2009;20:1453-1464.
5. Covic A, Kothawala P, Bernal M, Robbins S, Chalian A, Goldsmith D: Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009;24:1506-1523.
6. Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecky K: Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002;61:638-647.
7. London GM, Guerin AP, Marchais S, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-1740.
8. Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in endstage renal disease. Circulation 2002;106:2212-2217.
9. Hoeks A P G, Willekes C, Boutouyrie P, Brands PJ, Willigers JM, Reneman RS: Automated detection of artery wall thickness based on M-line signal processing. Ultrasound Med Biol 1997;23:1017-1023.
10. Friedwald WT, Levy RT, Fredrickson DS: Estimation of the concentration of low-density lipoprotein-cholesterol without the use of the preparation ultracentrifuge. Clin Chem 1972;18:499-502.
11. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE: Common carotid intimamedia thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation 1997;96:1432-1437.
12. Pascazio L, Bianco F, Giorgini A, Galli G, Curri G, Panzetta G: Echo color Doppler imaging of carotid vessels in hemodialysis patients: evidence of high levels of atherosclerotic lesions. Am J Kidney Dis 1996;28:713-720.
13. Goldsmith DR, Scott LJ, Cvetkovic RS, Plosker GL: Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. Drugs 2008;68:85-104.
14. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P: Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance he modialysis patients. Am Heart J 2005;149:820-825.
15. Krane V, Winkler K, Drechsler C, Lilienthal J, März W, Wanner C: Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 2008;74:1461-1467.
16. Stegmayr BG, Brannstrom M, Bucht S, Crougneau V, Dimeny E, Ekspong A, Eriksson M, Granroth B, Gröntoft KC, Hadimeri H, Holmberg B, Ingman B, Isaksson B, Johansson G, Lindberger K, Lundberg L, Mikaelsson L, Olausson E, Persson B, Stenlund H, Wikdahl AM, Nediat Study Group: Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scand J Urol Nephrol 2005;39:489-497.
17. United States Renal Data Systems. USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States: Bethesda, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007.
18. Raggi P, Kleerekoper M: Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic disease. C J Am Soc Nephrol 2008;3:836-843.
19. Guerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-1021.
20. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC: Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004;15:1943-1951.
21. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port KF: Association of elevated serum PO4, CaxPO4 product and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-2138.
22. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2002;342:1478-1483.
23. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F: Advanced coronary and carotid arteriopathy in young adults with childhood onset chronic renal failure. Circulation 2002;106:100-105.
24. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-252.
25. Kuang D, You H, Ding F, Xue J, Chen J, Ronco C, Gu Y: Intima-media thickness of the carotid artery and its correlation factors in maintenance hemodialysis patients: a crosssectional study. Blood Purif 2009;28:181-186.
26. Krasniac A, Drozdz M, Pasowicz M, Chmiel G, Michalek M, Szumilak D, Podolec P, Klimeczec P, Konieczynska M, Wicher-Muniak E, Tracz W, Khoa TN, Souberbielle JC, Drueke TB, Sulowicz W: Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol Dial Transplant 2007;22:515-521.
27. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-441.
28. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK: Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-1137.